Events

Cluster 5 2026 call European Commission online Brokerage event and info day
JAN
Wed
14
JAN
Thu
15

This was 3 weeks ago

Location

online

Programmes
Climate, Energy, Mobility

Join the Horizon Europe Cluster 5 info day on 15 January 2026 to explore the 2026 topics of the forthcoming work programme 2026-2027. This online event will be streamed via the European Commission’s web platform.

What to expect

  • Insights into the policy context

  • Guidance for preparing a high-quality proposal

  • Tips for enhancing the role of Social Sciences and Humanities in relevant topics

  • Interactive parallel sessions by thematic area to address specific questions on the topics

Here you can find more information on the event and register

The official publication of the Cluster 5 work programme 2026-2027 is expected any day now (estimated budget of €1.2 billion for the 2026 calls). A pre-publication version is already available.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.